Chorlada Paiboonrungruang

This study investigates metabolic changes in PCCA-deficient hepatocytes, showing reduced fatty acid oxidation and pyruvate carboxylation, leading to impaired gluconeogenesis and lipid synthesis.

This study shows that pyrimethamine inhibits mutant NRF2 by acting as a molecular glue to restore KEAP1 binding, enhancing therapy sensitivity in ESCC.

This paper identifies Pyrimethamine and its derivative WCDD115 as potent inhibitors of NRF2 by targeting DHFR and one-carbon metabolism, with WCDD115 showing 22-fold greater efficacy.